Associated tags: First generation, Generation, Second generation, Anxiety, National Medical Products Administration, Depression, Psychotherapy, DSM-IV codes, Insomnia, NMPA, Brain, Patient, Pharmaceutical industry, Traumatic brain injury, TBI
Locations: HOUSTON, TEXAS, US, BARDA, MIDDLE EAST, CHINA, OMAN, UNITED STATES
HOUSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) is pleased to invite investors to a webinar on May 23, 2024, at 4:15 p.m.
Key Points:
- HOUSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) is pleased to invite investors to a webinar on May 23, 2024, at 4:15 p.m.
- ET.
- A live Q&A session with White will follow the presentation.
- To register for the free webinar, please visit: https://redchip.zoom.us/webinar/register/WN_kFIw9RFmQnqrPAX03eC20w#/regi...
Questions can be pre-submitted to [email protected] or online during the live event.
HOUSTON, TEXAS, April 25, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) announced that the Company received notice from The Nasdaq Stock Market (“Nasdaq”) on April 23, 2024, notifying the Company that it has regained compliance with Nasdaq’s minimum bid price requirement under Nasdaq Rule 5550(a)(2).
Key Points:
- HOUSTON, TEXAS, April 25, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) announced that the Company received notice from The Nasdaq Stock Market (“Nasdaq”) on April 23, 2024, notifying the Company that it has regained compliance with Nasdaq’s minimum bid price requirement under Nasdaq Rule 5550(a)(2).
- Mark White, CEO of Nexalin, stated, “We remain committed to our mission of revolutionizing the treatment of mental health and neurological conditions through our safe, non-invasive, and drug-free neurostimulation technology.
- We believe our Nasdaq listing provides us with much greater exposure within the investment community, which is particularly important given the positive ongoing developments and anticipated upcoming milestones.
- I would like to extend my gratitude to our shareholders for your continued support and confidence in Nexalin's vision and capabilities.”
Retrieved on:
Wednesday, April 10, 2024
FDA,
Post-traumatic stress disorder,
Trial of the century,
Development,
Policy,
Privacy,
Sleep,
Journal,
UCSD,
HHS,
IP,
Government,
Optimism,
Traumatic brain injury,
Architecture,
Public sector,
Safety,
PTSD,
Collection,
Insomnia,
Jesse Russell,
Depression,
Federation,
Mental health,
Anxiety,
HALO,
University,
Concussion,
Science,
Patent,
Patient,
Physician,
Letter,
Pharmaceutical industry We believe our technology holds tremendous potential, including treatment applications for large and underserved markets within the fields of insomnia, depression, and anxiety.
Key Points:
- We believe our technology holds tremendous potential, including treatment applications for large and underserved markets within the fields of insomnia, depression, and anxiety.
- The broad potential of our technology is especially noteworthy given the growing number of patients seeking more effective non-pharmacological treatment options.
- We view this as a significant breakthrough, as mTBI is a prevalent and often debilitating condition with limited treatment options.
- The recent positive clinical results, growing market adoption, and continued innovation all point toward a bright future for Nexalin.
HOUSTON, TX, April 09, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced it has completed the first full production test run and successfully performed usability, feasibility design verification, and electrical safety testing for its new Gen-3 HALO™ Clarity 15 milliamp (mA) neurostimulation device in the U.S. As a result, the Company is now ramping up manufacturing in advance of its planned clinical trials and expects to produce approximately 500 units in the third quarter of 2024.
Key Points:
- Mark White, CEO of Nexalin Technology, stated, “I am thrilled to report that the HALO™Clarity passed a series of rigorous tests, validating our manufacturing process and illustrating that our device meets the highest product standards.
- Given this success, we are now accelerating production of the HALO™Clarity device to support our upcoming clinical trials.
- Not only does the HALO™Clarity device build on extensive clinical data demonstrating the potential therapeutic effect of our prior generation devices, but it adds a whole new level of functionality, enabling treatment from the comfort and convenience of one’s own home, as well as remote monitoring by a physician.
- Contingent upon FDA approval, the home-use aspect of HALO™ Clarity is expected to significantly reduce patient treatment costs, while increasing compliance with applicable standards.
HOUSTON, TX, April 04, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced that the United States Patent and Trademark Office (USPTO) has awarded U.S. Patent No.
Key Points:
- HOUSTON, TX, April 04, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced that the United States Patent and Trademark Office (USPTO) has awarded U.S. Patent No.
- The newly issued patent, entitled, “Transcranial Alternating Current Dynamic Frequency Stimulation Method for Anxiety, Depression and Insomnia (ADI),” covers the method of use utilized in the Company’s Gen-3 HALO Clarity™ system.
- Mark White, CEO of Nexalin Technology, stated, “This method of use patent award marks a major achievement for the Company and follows another recent patent covering our core technology.
- The Company’s technology uses a digital breakthrough in electrical waveforms to provide deep and painless brain neural stimulation.
Citadel,
Depression,
Department of Defence,
National War College,
Legislation,
Government,
Army Command,
Veteran,
Veterans' affairs,
General counsel,
Patient,
Insomnia,
Colonel,
TBI,
Policy,
Senior counsel,
University,
Anxiety,
Military personnel,
Military,
Traumatic brain injury,
OGC,
National Security Strategy,
Private law,
PTSD,
Nursing HOUSTON, TEXAS, April 02, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW), today announced the appointment of former Acting General Counsel to the Department of Veterans Affairs, William (“Bill”) A. Hudson, Jr., to the Company’s Military & Government Advisory Board (“Advisory Board”).
Key Points:
- HOUSTON, TEXAS, April 02, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW), today announced the appointment of former Acting General Counsel to the Department of Veterans Affairs, William (“Bill”) A. Hudson, Jr., to the Company’s Military & Government Advisory Board (“Advisory Board”).
- Nexalin’s Advisory Board provides strategic advice and counsel to support the Company’s advancement of its non-invasive, frequency-based, deep-brain stimulation devices in U.S. military and government agencies.
- Mr. Hudson is a partner in Tully Rinckey PLLC’s Washington, D.C. office where he focuses his practice on military, security clearance, and federal employment law.
- Mark White, CEO of Nexalin Technology stated, “We are honored to welcome Col. Bill Hudson to the Military & Government Advisory Board.
MEG,
Development,
Psychiatry,
Veteran,
Physician,
Post-traumatic stress disorder,
NSI,
Analysis of variance,
Patient,
UC,
RPQ,
Jesse Russell,
Radiology,
Human services,
PCS,
Concussion,
Trial of the century,
University,
McGill Pain Questionnaire,
Brain damage,
Pain,
ANOVA,
Vaccine,
PTSD,
MPQ,
Medical imaging HOUSTON, TEXAS, March 28, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced the positive results of a clinical study evaluating Nexalin’s Gen-2 tACS device for reducing pain in veteran patients with Mild Traumatic Brain Injury (mTBI). The study was conducted at The University of California, San Diego, and is further detailed in an abstract co-authored by the United States Department of Veterans Affairs (VA) San Diego Healthcare System, and the Radiology, Psychiatry and Neurosciences Departments of UC San Deigo.
Key Points:
- mTBI is a leading cause of sustained physical, cognitive, emotional, and behavioral deficits in veterans and the general public.
- However, the underlying pathophysiology is not completely understood, and there are few effective treatments for post-concussive symptoms (PCS).
- The study was conducted as a randomized, double-blind, placebo-controlled clinical trial over an eight-week period, with two groups being examined: an active tACS group and a sham tACS group.
- Mark White, CEO of Nexalin Technology, stated, "We are encouraged by the results of the clinical study, reinforcing the significant reduction in pain and other persistent symptoms of mild traumatic brain injury among veteran patients.
HOUSTON, TEXAS, March 14, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced that it has commenced sales of its second generation (Gen-2), 15 milliamp (mA) neurostimulation device into a new mental health center in Oman, dedicated to the use of Nexalin’s neurostimulation device for the treatment of patients with substance abuse disorder (SUD).
Key Points:
- HOUSTON, TEXAS, March 14, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced that it has commenced sales of its second generation (Gen-2), 15 milliamp (mA) neurostimulation device into a new mental health center in Oman, dedicated to the use of Nexalin’s neurostimulation device for the treatment of patients with substance abuse disorder (SUD).
- As previously announced , Nexalin was recently granted regulatory approval for its Gen-2, 15 milliamp (mA) neurostimulation device by the Sultanate of Oman’s Ministry of Health.
- Mark White, CEO of Nexalin Technology, stated, “We are pleased to commence commercial sales of our Gen-2 neurostimulation device in Oman following regulatory approval by the Sultanate of Oman’s Ministry of Health.
- Importantly, the new center is exclusively focused on providing comprehensive treatment of patients with SUD, utilizing Nexalin’s Gen-2 neurostimulation device, with plans to expand into the treatment of other mental health disorders.
Retrieved on:
Wednesday, March 13, 2024
Diagnosis,
Depression,
Washington Convention Center,
Government,
Development,
Veteran,
Walter,
Patient,
Insomnia,
Concussion,
TBI,
Anxiety,
MTEC,
Chronic pain,
Traumatic brain injury,
Dementia,
PTSD,
Medical device HOUSTON, TEXAS, March 13, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW), today announced it was selected and provided a poster presentation at the “State of the Technology Meeting: Neurotrauma Diagnosis, Monitoring, and Assessment” on March 12, 2024, which was held at the Walter E. Washington Convention Center in Washington, D.C.
Key Points:
- The U.S. Army Medical Research and Development Command’s (USAMRDC) Combat Casualty Care Research Program (CCCRP) Neurotrauma Portfolio and the Biomedical Advanced Research and Development Authority (BARDA), with support of MTEC, hosted the State of the Technology meeting focused on non-invasive neuroassessment tools.
- This was an ideal venue for our poster presentation as the conference attendees included many of the leading thought leaders and decision-makers from both the public and private sectors.
- Notably, both the DoD and BARDA’s concerns continue to grow surrounding TBI, and we’re seeing the US Government significantly invest in new, non-drug therapeutic options to address TBI in support of struggling warfighters and veterans.
- We could not have been more pleased with the overwhelming response to our presentation and look forward to providing more details on our latest study in an upcoming abstract publication.”
Incidence,
PSQI,
Ageing,
Overalls,
Capital Medical University,
Hospital,
Sleep,
Trial of the century,
Pittsburgh Sleep Quality Index,
Jesse Russell,
Insomnia,
Prevalence,
TST,
Fatigue,
Patient,
Journal,
Personality disorder,
SOL,
Clinical trial,
Pharmaceutical industry HOUSTON, TEXAS, March 06, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced positive results of a clinical study of its Gen-2 tACS device (“tACS”) for the treatment of chronic insomnia. This clinical study, conducted at Xuanwu Hospital of Capital Medical University in Beijing and Beijing Anding Hospital, evaluated the treatment response of 120 adult participants who were divided into two prespecified age subgroups.
Key Points:
- Key data reported from the study suggests that tACS ameliorates chronic insomnia, and that age can impact the extent of the resulting improvement from tACS treatment.
- Older participants (ages 50 and over) experienced comparatively more significant benefits from tACS, in terms of enhanced sleep quality, efficiency and overall insomnia reduction (p
- This is attributed to the natural changes in sleep physiology that occur with aging and the distinct manifestations of insomnia symptoms in older individuals.
- The clinical study’s results, which were published in the Journal of Psychiatric Research, showed that tACS meaningfully reduced the severity of insomnia and enhanced sleep quality and efficiency.
